J. Bottsford-Miller, A. Sanguino, D. Thanapprapasr
Apr 15, 2011
Citations
0
Influential Citations
3
Citations
Quality indicators
Journal
Cancer Research
Abstract
Focal adhesion kinase (FAK) represents a central point of convergence for many signaling pathways implicated in cancer progression and metastasis. Pazopanib is a pan-VEGFR and PDGFR inhibitor. In the present study, we examined whether pazopanib treatment would result in greater anti-tumor activity in combination with the novel FAK-inhibitor, GSK2256098. The in vitro effects of GSK2256098 on invasion and migration were examined using the HeyA8 and SKOV3-IP1 human ovarian cancer cell lines. In vivo effects of pazopanib with and without GSK2256098 were then assessed using an orthotopic mouse model of human ovarian cancer. GSK2256098 resulted in reduced levels of FAK phosphorylation at Y397 (pFAKY397) at 1μM concentration in SKOV3-IP1 cells. GSK2256098 resulted in a reduced invasion (p Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-230. doi:10.1158/1538-7445.AM2011-LB-230